Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply

被引：0
|
作者：
Atia, Ohad [1 ]
Goren, Idan [2 ,3 ,4 ]
Yanai, Henit [2 ,3 ]
机构：
[1] Hebrew Univ Jerusalem, Juliet Keidan Inst Pediat Gastroenterol Hepatol &, Shaare Zedek Med Ctr, Jerusalem, Israel
[2] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[4] Cleveland Clin, Lerner Res Inst, Dept Inflammat & Immun, Cleveland, OH USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 57卷 / 10期
关键词：
D O I：
10.1111/apt.17504
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1184 / 1185
页数：2
相关论文
共 50 条
  • [31] Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Authors' reply
    Khan, N.
    Almukhtar, R. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) : 1121 - 1122
  • [32] Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply
    Yiu, Tsz Hong
    Ko, Yanna
    Pudipeddi, Aviv
    Natale, Patrizia
    Leong, Rupert W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (01) : 103 - 104
  • [33] Letter: Association of myokines with disease progression and outcomes in patients with alcohol-associated liver disease-Authors' reply
    Kaur, Parminder
    Verma, Nipun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1477 - 1478
  • [34] Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply
    Burisch, Johan
    Langholz, Ebbe
    Munkholm, Pia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (09) : 1239 - 1240
  • [35] Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply
    Mahadevan, U.
    Vermeire, S.
    Lasch, K.
    Abhyankar, B.
    Bhayat, F.
    Blake, A.
    Dubinsky, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (03) : 388 - 389
  • [36] Letter: deleterious effects of smoking on post-operative Crohn's disease - authors' reply
    To, N.
    Gracie, D. J.
    Ford, A. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (11) : 1248 - 1248
  • [37] Letter: Association of Myokines With Disease Progression and Outcomes in Patients With Alcohol-Associated Liver Disease-Authors' Reply'
    Kaur, Parminder
    Garg, Pratibha
    Verma, Nipun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1639 - 1640
  • [38] Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply
    Simsek, Melek
    de Boer, Nanne K. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (01) : 216 - 217
  • [39] Maintenance infliximab for Crohn's disease - Reply
    Hanauer, SB
    LANCET, 2002, 360 (9345): : 1602 - 1603
  • [40] Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply
    Mahmoud, Remi
    Schultheiss, Johannes P. D.
    Fidder, Herma H.
    Oldenburg, Bas
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 499 - 500
12345